Vgenomics, a leading Delhi-based biotech firm, has formed an exclusive partnership with Dr. Shroff’s Charity Eye Hospital—one of India’s premier institutions in eye care and research—to validate and commercialize a groundbreaking tear-based biomarker, VSP-2224, for early detection of keratoconus. This progressive eye disorder affects the cornea and can lead to serious vision loss if not diagnosed in time.
The Urgent Need for Early Detection
Keratoconus alters the shape and structure of the cornea, gradually impairing vision. Unfortunately, conventional diagnostic methods rely heavily on imaging, which typically identifies the disease only after significant corneal damage has already occurred. With keratoconus affecting over 2% of India’s population—and with incidence rising rapidly in the MENA region—early and accessible screening solutions are more crucial than ever.
A Breakthrough in Tear-Based Biomarkers
In a significant scientific development, researchers at Dr. Shroff’s Eye Hospital discovered VSP-2224, a novel protein biomarker present in tear fluid. They identified it using RgenX-LENS, Vgenomics’ proprietary AI-powered multi-omics biomarker and drug discovery platform. Unlike current diagnostic tools, this biomarker enables detection of keratoconus before visible corneal thinning appears—paving the way for earlier interventions and better clinical outcomes.
Shifting the Focus to Preventive Eye Care
“We’re proud to partner with Dr. Shroff’s Eye Hospital to bring VSP-2224 into clinical practice,” said Dr. Rahila Sardar, Founder and CEO of Vgenomics. “This collaboration represents a vital shift from late-stage diagnosis to early, preventive care in ophthalmology.”
Towards Non-Invasive, Accessible Screening
“Tear-based diagnostics are a game-changer,” noted Dr. Virender Singh Sangwan, Director of Innovation and Translational Research at Dr. Shroff’s. “This partnership helps us transform a tear-based biomarker into a viable clinical diagnostic test—with future potential for targeted therapies.”
As per the press release, Dr. Anil Tiwari further emphasized the public health impact. He said, “Tear-based testing is non-invasive, easy to administer, and ideal for early detection programs. It is especially suited for India’s diverse healthcare settings.”
Clinical Validation and Future Applications
Currently, Vgenomics and Dr. Shroff’s Eye Hospital are validating VSP-2224 across a wide cohort. This includes patients with keratoconus, healthy individuals, and those already receiving treatment. In parallel, Vgenomics is developing OcuTear, a rapid point-of-care diagnostic panel for ocular surface diseases. VSP-2224 will serve as the lead marker in this new platform for keratoconus detection.
Redefining the Future of Keratoconus Care
This partnership and scientific breakthrough signal a new era in eye care—one that is proactive, precise, and patient-friendly. Vgenomics and Dr. Shroff’s Eye Hospital are enabling early diagnosis through a simple, tear-based test. This innovation is setting a new standard for keratoconus screening and care in India and beyond.